Bioventus Inc. (NASDAQ: BVS) reported Q1 EPS of ($0.07), $0.07 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $129.45 million versus the consensus estimate of $117.3 million.

GUIDANCE:

Bioventus Inc. sees Q2 2024 EPS of $0.25-$0.33, versus the consensus of $0.15. Bioventus Inc. sees Q2 2024 revenue of $535-550 million, versus the consensus of $528.1 million.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.